Pharmaceuticals Blog
Congress gets involved with Johnson & Johnson, FDA over stents
August 15th, 2007 by Todd HagemanThe Washington Post and Pharmalot report that lawmakers have sent letters to Johnson & Johnson and the U.S. Food and Drug Administration asking why Cypher stents were allowed to be sold after inspections and studies released as early as 2004 showed numerous manufacturing problems.
The Aug. 13 letters to the FDA and Johnson & Johnson were sent by U.S. Rep. John Dingell, chairman of the House Committee on Energy and Commerce, and U.S. Rep. Bart Stupak, chairman of the Subcommittee on Oversight and Investigations. Both lawmakers are Michigan Democrats.
If you or someone you know has encountered problems with stents, please contact Todd Hageman toll free at 1-877-767-3108.
